Abstract
This Practice Point commentary discusses the experience of Shapiro et al. with renal allograft recipients at a single center who underwent significant minimization of immunosuppressive treatment with alemtuzumab induction and tacrolimus monotherapy (weaned to three times weekly by 1 year after transplantation). Donor-specific antibodies (DSAs) against human leukocyte antigen were monitored after transplantation in some patients. Although 44% of patients did not develop acute rejection or DSAs and had excellent 2-year graft survival (96%), spaced weaning was not attempted in 20% of patients, generally those with early rejection and poor allograft function. During tapering, 20% of patients developed acute rejection and 15% developed DSAs. Two-year graft survival was 63% in patients for whom weaning was not attempted and 78% in patients who experienced acute rejection. Alemtuzumab preconditioning with tacrolimus monotherapy and spaced weaning increased the risk of acute rejection and development of DSAs. Patients should be carefully selected for this protocol and monitored closely for DSAs. Results of a long-term controlled trial that includes protocol biopsies are required to reach more-definitive conclusions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shapiro R et al. (2008) Alemtuzumab preconditioning with tacrolimus monotherapy—the impact of serial monitoring for donor-specific antibody. Transplantation 85: 1125–1132
Ciancio G and Burke GW 3rd (2008) Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 8: 15–20
Shapiro R et al. (2003) Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 238: 520–525
Akalin E and Pascual M (2006) Sensitization after kidney transplantation. Clin J Am Soc Nephrol 1: 433–440
Akalin E and Watschinger B (2007) Antibody-mediated rejection. Semin Nephrol 27: 393–407
Brouard S et al. (2007) Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 104: 15448–15453
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Akalin, E. Immunosuppression minimization protocols: how should they be monitored?. Nat Rev Nephrol 4, 484–485 (2008). https://doi.org/10.1038/ncpneph0910
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0910
This article is cited by
-
Blocking Effect of an Immuno-Suppressive Agent, Cynarin, on CD28 of T-Cell Receptor
Pharmaceutical Research (2009)